

For Immediate Release

CONTACT:

Paul Kidwell
617-296-3854
paul_kidwell@hotmail.com

News Release

**Enanta Pharmaceuticals Awarded Fourth Patent Covering
Novel Macrolide Antibiotics**



WATERTOWN, Mass., June 17, 2003 – Enanta Pharmaceuticals, Inc. (www.enanta.com), a chemistry-driven biopharmaceutical company, announced today that the United States Patent and Trademark Office has issued the fourth patent associated with the company's antibacterial research program. This latest patent based on novel compounds synthesized by Enanta scientists is: Number 6,576,615 and titled "4'-O-Substituted Tylosin Analogs." Enanta's antibacterial research and development is focused on the development of novel macrolide antibiotics that exhibit effectiveness against the target resistant pathogens for respiratory tract infections.

"This latest macrolide patent represents the ongoing progress made by Enanta's scientists towards the development of compounds with improved potential to treat respiratory tract infections," said Spiros Jamas, President and CEO of Enanta. "Our growing intellectual property platform includes over 20 pending patent applications emphasizing the success we have had to date in applying Enanta's chemistry expertise and creating multiple, proprietary classes of compounds."

The present invention relates to novel macrolides having antibacterial activity and useful in the treatment and prevention of bacterial infections. The patent describes the chemical synthesis of a novel class of 4'-substituted 16-membered macrolides derived from tylosin. Tylosin belongs to the class of 16-membered ring macrolide antibiotics that constitute a clinically useful series of naturally occurring compounds within the macrolide class. Enanta's Macrolide program uses synthetic chemistry and macrocyclic chemistry approaches to alter established macrolide natural products thus creating novel compounds that overcome bacterial resistance and have improved biological profiles.

- more -

About Enanta

Headquartered in Watertown, Mass., Enanta Pharmaceuticals is using its cutting-edge chemistry technology and capabilities to create new intellectual properties by transforming existing drugs, natural products, and biologically active peptides into novel, small-molecule drugs. The Company is initially focusing on new chemical entities derived from existing drugs that address significant unmet medical needs: (a) new-generation macrolide antibiotics to overcome bacterial resistance; (b) anti-inflammatory drugs for a variety of indications, including asthma, psoriasis and inflammatory bowel diseases, and (c) novel antiviral agents targeted to the Hepatitis C virus (HCV).

###